Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. [electronic resource]
Producer: 20170901Description: 5119-31 p. digitalISSN:- 1476-5594
- Animals
- Antineoplastic Agents -- administration & dosage
- Apoptosis -- drug effects
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Drug Resistance, Neoplasm -- genetics
- Humans
- Leukemia, Myeloid, Acute -- drug therapy
- Mice
- Morpholines -- administration & dosage
- Mutation
- Niacinamide -- administration & dosage
- Phenylurea Compounds -- administration & dosage
- Phosphatidylinositol 3-Kinases -- genetics
- Phosphoinositide-3 Kinase Inhibitors
- Protein Kinase Inhibitors -- administration & dosage
- Signal Transduction -- drug effects
- Sorafenib
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Triazines -- administration & dosage
- Xenograft Model Antitumor Assays
- fms-Like Tyrosine Kinase 3 -- genetics
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.